Ballentine Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $577K | Buy |
6,378
+127
| +2% | +$10.6K | 0.01% | 519 |
|
|
2026
Q1 | $501K | Buy |
6,251
+348
| +6% | +$28.7K | 0.01% | 531 |
|
|
2025
Q4 | $503K | Sell |
5,903
-174
| -3% | -$14.3K | 0.01% | 499 |
|
|
2025
Q3 | $473K | Buy |
6,077
+5
| +0.1% | +$391 | 0.01% | 526 |
|
|
2025
Q2 | $475K | Buy |
6,072
+963
| +19% | +$71.8K | 0.01% | 500 |
|
|
2025
Q1 | $370K | Sell |
5,109
-375
| -7% | -$26.8K | 0.01% | 546 |
|
|
2024
Q4 | $406K | Buy |
5,484
+810
| +17% | +$56.7K | 0.01% | 492 |
|
|
2024
Q3 | $308K | Sell |
4,674
-670
| -13% | -$48.7K | 0.01% | 575 |
|
|
2024
Q2 | $494K | Buy |
5,344
+108
| +2% | +$9.56K | 0.01% | 410 |
|
|
2024
Q1 | $500K | Buy |
5,236
+984
| +23% | +$82.7K | 0.01% | 388 |
|
|
2023
Q4 | $324K | Sell |
4,252
-831
| -16% | -$57.8K | 0.01% | 480 |
|
|
2023
Q3 | $352K | Sell |
5,083
-570
| -10% | -$45.8K | 0.01% | 398 |
|
|
2023
Q2 | $533K | Buy |
5,653
+184
| +3% | +$16K | 0.01% | 302 |
|
|
2023
Q1 | $452K | Buy |
5,469
+563
| +11% | +$44.3K | 0.01% | 317 |
|
|
2022
Q4 | $366K | Buy |
4,906
+882
| +22% | +$68K | 0.01% | 336 |
|
|
2022
Q3 | $333K | Buy |
4,024
+991
| +33% | +$95.4K | 0.01% | 313 |
|
|
2022
Q2 | $288K | Buy |
3,033
+886
| +41% | +$91.7K | 0.01% | 333 |
|
|
2022
Q1 | $252K | Buy |
2,147
+280
| +15% | +$31.4K | 0.01% | 394 |
|
|
2021
Q4 | $242K | Buy |
1,867
+5
| +0.3% | +$583 | 0.01% | 405 |
|
|
2021
Q3 | $211K | Buy |
+1,862
| New | +$213K | 0.01% | 388 |
|
|
2020
Q4 | – | Sell |
-4,447
| Closed | -$355K | – | 394 |
|
|
2020
Q3 | $355K | Sell |
4,447
-960
| -18% | -$74.9K | 0.02% | 259 |
|
|
2020
Q2 | $374K | Buy |
5,407
+67
| +1% | +$4.76K | 0.02% | 235 |
|
|
2020
Q1 | $335K | Sell |
5,340
-288
| -5% | -$20.8K | 0.02% | 235 |
|
|
2019
Q4 | $437K | Hold |
5,628
| – | – | 0.02% | 241 |
|
|
2019
Q3 | $412K | Buy |
5,628
+381
| +7% | +$26.8K | 0.02% | 238 |
|
|
2019
Q2 | $323K | Buy |
5,247
+1,431
| +38% | +$86.5K | 0.02% | 277 |
|
|
2019
Q1 | $243K | Buy |
+3,816
| New | +$218K | 0.01% | 284 |
|
|
2016
Q4 | – | Sell |
-6,474
| Closed | -$260K | – | 214 |
|
|
2016
Q3 | $260K | Sell |
6,474
-171
| -3% | -$6.44K | 0.02% | 152 |
|
|
2016
Q2 | $222K | Buy |
+6,645
| New | +$227K | 0.02% | 188 |
|
Other funds holding EW
Ballentine Partners's EW Position: Q2 2026 in Review
Ballentine Partners increased its Edwards Lifesciences (EW) stake by 2% in Q2 2026, buying an estimated $10.6K and bringing the position to 6,378 shares worth $577K. The position accounts for 0.01% of the portfolio, ranked #519.
Ballentine Partners first reported a position in EW in Q2 2016 and has held it in 29 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Ballentine Partners held 6,378 shares of Edwards Lifesciences worth $577K as of Q2 2026.
- Ballentine Partners bought 127 Edwards Lifesciences shares in Q2 2026, an estimated $10.6K.
- Edwards Lifesciences made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #519 holding.
- Ballentine Partners first reported a position in Edwards Lifesciences in Q2 2016 and has held it in 29 quarters since.
- 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.